venus concept is a leader in the global medical aesthetic market, pairing best-in-class technology with the first and only true subscription model in the industry. our goal is to help both new and established practices succeed in this growing field. we understand the challenges of breaking into and being successful in the aesthetics industry, and that’s why we’re changing the game with an innovative solution. the secret is in our industry-unique subscription model. in partnering with venus concept, aesthetic professionals worldwide gain access to never-before-seen business features such as the most comprehensive warranty program, unmatched marketing support, continuous clinical education, valuable practice enhancement programs, and more. together with this business model, our collection of aesthetic systems—including venus versa™, venus legacy™, venus velocity™, venus viva™, venus freeze plus™, and venus skin™—are setting higher industry standards and improving the quality of life for
Company profile
Ticker
VERO
Exchange
Website
CEO
Domenic Serafino
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Restoration Robotics, Inc., Restoration Robotics Inc
SEC CIK
Corporate docs
Subsidiaries
Venus Concept Mexico SA • Venus Concept GmbH • Venus Concept Australia PTY Ltd • Venus Concept USA Inc. • Venus Concept Canada Corp. • Venus Concept UK Limited • Venus Concept Ltd • Venus Concept Israel Ltd • Venus Concept (Shanghai) Co., Ltd. • Venus Concept Japan Co., Ltd. ...
VERO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
18 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Apr 24
S-3
Shelf registration
8 Apr 24
S-1
IPO registration
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
1 Apr 24
8-K
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
25 Mar 24
D
$1.10 mm in options / securities to be acquired, sold $1.10 mm, 2 investors
7 Mar 24
8-K
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
27 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
Transcripts
VERO
Earnings call transcript
2023 Q4
1 Apr 24
VERO
Earnings call transcript
2023 Q3
14 Nov 23
VERO
Earnings call transcript
2023 Q2
14 Aug 23
VERO
Earnings call transcript
2023 Q1
15 May 23
VERO
Earnings call transcript
2022 Q4
27 Mar 23
VERO
Earnings call transcript
2022 Q3
11 Nov 22
VERO
Earnings call transcript
2022 Q2
12 Aug 22
VERO
Earnings call transcript
2022 Q1
13 May 22
VERO
Earnings call transcript
2021 Q4
28 Mar 22
VERO
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
1 Mar 24
SC 13D/A
MASTERS CAPITAL MANAGEMENT LLC
29 Feb 24
SC 13D/A
EW Healthcare Partners, L.P.
28 Feb 24
SC 13D/A
Madryn Asset Management, LP
22 Feb 24
SC 13D/A
EW Healthcare Partners, L.P.
22 Jan 24
4
Change in insider ownership
19 Jan 24
SC 13D/A
EW Healthcare Partners, L.P.
23 Oct 23
4
Change in insider ownership
20 Oct 23
SC 13D/A
Madryn Asset Management, LP
12 Oct 23
4
Change in insider ownership
6 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.93 mm | 4.93 mm | 4.93 mm | 4.93 mm | 4.93 mm | 4.93 mm |
Cash burn (monthly) | 398.67 k | 154.25 k | 3.09 mm | 3.05 mm | 1.36 mm | 1.29 mm |
Cash used (since last report) | 2.72 mm | 1.05 mm | 21.11 mm | 20.79 mm | 9.27 mm | 8.81 mm |
Cash remaining | 2.20 mm | 3.87 mm | -16.19 mm | -15.87 mm | -4.35 mm | -3.89 mm |
Runway (months of cash) | 5.5 | 25.1 | -5.2 | -5.2 | -3.2 | -3.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 2 |
Closed positions | 14 |
Increased positions | 0 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 1.19 bn |
Total shares | 28.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HealthQuest Partners II | 11.71 mm | $2.11 mm |
Saudi Economic & Development Securities | 10.08 mm | $17.14 mm |
Longitude Capital Partners II | 3.47 mm | $1.03 mm |
EW Healthcare Partners | 3.16 mm | $10.24 mm |
Masters Capital Management | 333.34 k | $700.01 mm |
Madryn Asset Management | 112.04 k | $235.28 mm |
Vanguard | 72.32 k | $151.87 mm |
PFG Investments | 14.00 k | $29.40 mm |
Commonwealth Equity Services | 12.42 k | $26.00 k |
Geode Capital Management | 12.26 k | $26.12 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Oct 23 | EW Healthcare Partners | Senior Convertible Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 3.98 | 502,513 | 2.00 mm | 1,575,810 |
4 Oct 23 | Madryn Asset Management | Series X Convertible Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 0 | 248,755 | 0.00 | 248,755 |
8 Sep 23 | EW Healthcare Partners | Senior Convertible Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 3.42 | 292,398 | 1.00 mm | 1,073,297 |
11 Aug 23 | Michael Mandarello | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 233 | 0.00 | 1,491 |
11 Aug 23 | Michael Mandarello | Common Stock | Grant | Acquire A | No | No | 0 | 834 | 0.00 | 1,724 |
News
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
8 Apr 24
Venus Concept Q4 GAAP EPS $(2.01) Misses $(1.18) Estimate, Sales $18.13M Miss $22.45M Estimate
1 Apr 24
Earnings Scheduled For April 1, 2024
1 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
27 Feb 24
Gold Moves Lower; Pilgrim's Pride Earnings Top Views
26 Feb 24
Press releases
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
15 Apr 24
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
8 Apr 24
Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
3 Apr 24
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
25 Mar 24
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
28 Feb 24